Marle Group, a medical device manufacturer headquartered in France, has entered into an agreement to acquire 3D Medlab, a provider of additively manufactured medical components headquartered in Marignane, France.
Marle Group has seven production facilities exclusively focused on orthopaedic implant manufacturing for OEMs globally. 3D Medlab specialises in engineering, design and development, and the production of additively manufactured metal and polymer implants, as well as components for the ortho, spine, trauma, and cardio markets.
According to Marle Group, the acquisition of 3D Medlab expands its contract manufacturing offering to create a total end-to-end AM solution. This solution supports research and innovation, product development, prototyping, various manufacturing platforms (additive, forging, casting, or subtractive machining), inspection and quality, complete packaging, and delivery of complex finished product.
Antonio Gil, president and Heimo Wabusseg, CEO, Marle Group, stated “We are extremely excited about this strategic alliance and the opportunity to combine our forging, casting, and machining expertise with a proven 3D implant company. We had been looking to join forces with a partner to execute our growth strategy in the United States and provide our Marle Group customers with the latest in implant technology. This merger with 3D Medlab was a perfect fit for the Marle Team, and we are confident that we will increase market share in 2021 and beyond.”
Frank D. Noone, vice president, Marle America, commented, “The acquisition of 3D Medlab represents a milestone in our strategy to strengthen Marle Group’s medical device contract manufacturing position in the orthopaedic and spine market in the United States. We are excited to partner with 3D Medlab because of a shared commitment to constant innovation and a laser focus on customer satisfaction. This will give us an opportunity to gain access to new accounts and increase our presence in existing accounts by providing 3D printed implants and with the full scope of the Marle Group’s technical expertise, proven quality products and value-added service.”
Gaël Volpi, CEO and founder, 3D Medlab, added, “This combination of our innovative cultures will allow us to expand and stretch our strategic value to our customers globally by fully encompassing the diverse scope of manufacturing techniques and platforms between seven facilities. Marle also has an excellent reputation in the med device space for collaboration with their customers and speed to market which aligns with our core values at 3D MEDLAB. Joining the Marle Group enables our company to expand exposure to our innovations, keep our R&D value and accelerate our growth as part of a leading global medical device contract manufacturer focused on providing orthopaedic implant and cardiovascular solutions to OEM’s.”